Abintus Bio Revenue and Competitors

Abintus Bio is leading the field of in vivo immune cell reprogramming. We are pursuing products that modulate immune cells from within their native environment to enhance patient access and patient outcomes. Abintus Bio, Inc. is a San Diego-based, preclinical stage gene therapy company focused on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies. Abintus is leveraging over $275 million of prior investment in the advancement of in vivo retroviral technology and has over 83 years of collective experience and know-how with the engineering, manufacturing and development of in vivo retroviral vectors, including the treatment of over 350 patients through Phase 3 registration trials and late-stage commercial launch planning.